BIOMARIN PHARMACEUTICAL INC Deferred Income Tax Expense (Benefit) in USD from Q1 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Biomarin Pharmaceutical Inc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2010 to Q1 2025.
  • Biomarin Pharmaceutical Inc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2025 was $28.4M, a 9875% increase year-over-year.
  • Biomarin Pharmaceutical Inc annual Deferred Income Tax Expense (Benefit) for 2024 was $56.1M.
  • Biomarin Pharmaceutical Inc annual Deferred Income Tax Expense (Benefit) for 2023 was -$45M, a 13.6% increase from 2022.
  • Biomarin Pharmaceutical Inc annual Deferred Income Tax Expense (Benefit) for 2022 was -$52.1M, a 234% decline from 2021.
Deferred Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)

BIOMARIN PHARMACEUTICAL INC Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $28.4M +$28.1M +9875% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-02
Q1 2024 $285K +$6.65M Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-02
Q1 2023 -$6.36M -$11.2M -233% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-26
Q1 2022 $4.8M +$1.47M +43.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-04-28
Q1 2021 $3.34M -$7.27M -68.5% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-29
Q1 2020 -$71.5M $10.6M +$11.3M Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-30
Q4 2019 -$82.8M -$9.76M Oct 1, 2019 Dec 31, 2019 10-K 2022-02-25
Q3 2019 -$45.2M Jul 1, 2019 Sep 30, 2019 10-Q/A 2019-11-04
Q2 2019 -$27.1M Apr 1, 2019 Jun 30, 2019 10-Q/A 2019-11-04
Q1 2019 -$704K +$13.3M +95% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-01
Q1 2018 -$14M -$3.55M -34% Jan 1, 2018 Mar 31, 2018 10-Q 2019-04-29
Q1 2017 -$10.4M +$10.9M +51.1% Jan 1, 2017 Mar 31, 2017 10-Q 2018-04-27
Q1 2016 -$21.4M -$13.6M -174% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-04
Q1 2015 -$7.8M -$7.62M -4258% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-02
Q1 2014 -$179K -$136K -316% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-05
Q1 2013 -$43K -$755K -106% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-02
Q1 2012 $712K -$3.2M -81.8% Jan 1, 2012 Mar 31, 2012 10-Q 2013-04-29
Q1 2011 $3.91M +$3.91M Jan 1, 2011 Mar 31, 2011 10-Q 2012-04-30
Q1 2010 $0 Jan 1, 2010 Mar 31, 2010 10-Q 2011-04-29

BIOMARIN PHARMACEUTICAL INC Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $56.1M +$101M Jan 1, 2024 Dec 31, 2024 10-K 2025-02-24
2023 -$45M +$7.11M +13.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-24
2022 -$52.1M -$36.5M -234% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-24
2021 -$15.6M +$874M +98.2% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-26
2020 -$890M -$807M -975% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-27
2019 -$82.8M -$14.4M -21% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-25
2018 -$68.4M -$113M -254% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-26
2017 $44.5M +$273M Jan 1, 2017 Dec 31, 2017 10-K 2020-02-27
2016 -$228M -$151M -197% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-28
2015 -$76.8M -$51.2M -200% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-26
2014 -$25.6M -$16.7M -188% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-27
2013 -$8.91M +$1.02M +10.2% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-29
2012 -$9.92M -$14.3M -327% Jan 1, 2012 Dec 31, 2012 10-K 2015-03-02
2011 $4.36M +$235M Jan 1, 2011 Dec 31, 2011 10-K 2014-02-26
2010 -$231M Jan 1, 2010 Dec 31, 2010 10-K 2013-02-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.